| Name | Title | Contact Details |
|---|---|---|
William Blake |
Chief Technology Officer | Profile |
A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.
Progenitor Cell Therapy, LLC, a cell therapy services company, supports the development and commercialization of cellular therapies. It offers manufacturing practices-compliant services for pre-clinical and clinical development, as well as involves in the commercialization of cellular therapies for clients in the United States and internationally.
Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering discovery opportunities and services for life science partners, and merging industrial and academic efforts to bring new